Publications (1)0 Total impact
Article: Metronomic chemotherapy as a palliative treatment in poor performance status patients with advanced epithelial ovarian carcinoma[show abstract] [hide abstract]
ABSTRACT: ObjectiveThe aim of our study was to evaluate the clinical efficacy and tolerability of metronomic chemotherapy in patients with advanced ovarian carcinoma. MethodsFifteen patients with advanced ovarian carcinoma and bad performance status were subjected to daily cyclophosphamide (CTX) after failure of 1st line chemotherapy which included paclitaxel and carboplatin. Evaluation of the cases during treatment as regard treatment side effects and progression free survival. ResultsPatients could tolerate low dose oral cyclophosphamide treatment without considerable side effects with improvement of performance status. The mean progression free survival was 12 months. ConclusionLow dose oral cyclophosphamide could be considered as a palliative treatment of pretreated ovarian carcinomas with poor performance status. Key wordsmetronomic–chemotherapy–ovarian carcinomaThe Chinese-German Journal of Clinical Oncology 05/2012; 10(9):531-534.